Floatz logo

Wild-Type Reovirus

Recurrent Childhood Anaplastic Oligodendroglioma

Mayo ClinicPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Recurrent Childhood Anaplastic Oligodendroglioma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
City of Hope Medical Center
Phase 2BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
Carboplatin
Oliver Jonas
Phase 2BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

Wild-Type Reovirus is also rated in:

exocrine pancreatic carcinomaDormant
B
Indicative ·
57 / 100
View asset →
pancreatic acinar cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →